<DOC>
	<DOCNO>NCT02681809</DOCNO>
	<brief_summary>The purpose study assess efficacy safety 3 intravitreal injection ocriplasmin ( 0.0625mg 0.125mg ) , subject moderate severe non-proliferative diabetic retinopathy ( NPDR ) , induce total posterior vitreous detachment ( PVD ) order reduce risk disease progression proliferative diabetic retinopathy ( PDR ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Ocriplasmin Inducing Total PVD Subjects With NPDR</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Vitreous Detachment</mesh_term>
	<mesh_term>Fibrinolysin</mesh_term>
	<criteria>Male female age 18 year older Bestcorrected visual acuity ( BCVA ) 65 letter read great ( Snellen equivalent 20/50 good ) study eye HbA1c ≤ 12 % , assessed central laboratory Moderate severe NPDR per ETDRS Severity Scale , base 7 standard field stereo colour fundus photograph Central subfield thickness ≤ 340µm Spectralis SDOCT ≤ 320µm nonSpectralis SD OCT study eye , without mild centreinvolved diabetic macular oedema No evidence total PVD study eye Written inform consent obtain subject prior screening procedure History current ocular condition study eye may interfere assessment progression PDR Presence epiretinal membrane study eye Presence foveal ischemia study eye Presence preretinal vitreous haemorrhage study eye Presence iris angle neovascularisation study eye Any active ocular / intraocular infection inflammation either eye Aphakic study eye Uncontrolled hypertension opinion Investigator Pseudoexfoliation , Marfan 's syndrome , phacodonesis find Investigator 's opinion suggest lens / zonular instability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>